A new cloud-based platform called AdaptiveFlow uses AI to accelerate the search for new drugs. The system employs machine learning models to rapidly screen large libraries of chemical compounds, identifying potential candidates for specific diseases much faster than traditional methods. This could significantly reduce the time and cost of bringing new therapies to market. The platform is already being tested in collaboration with pharmaceutical companies for various therapeutic areas, including cancer and neurological disorders.
About the Author
